"mankhwala odabwitsa ochepetsa thupi" ali pafupi kulowa China!Novo Nordisk China ikutsimikizira kuti Semaglutide yochepetsa thupi idzavomerezedwa chaka chino

"mankhwala odabwitsa ochepetsa thupi" ali pafupi kulowa ku China!Novo Nordisk China ikutsimikizira kuti Semaglutide yochepetsa thupi idzavomerezedwa chaka chino
March 8, nkhani yakuti Novo Nordisk ikuyembekezeka kuchepetsa kulemera kwa Semaglutide Wegovy idzavomerezedwa ku China chaka chino, mankhwalawo adzakhala chiyambi cha odwala odzidalira okha, ndipo pali malire kwa chiwerengero cha odwala.Pachifukwa ichi, Novo Nordisk China adatsimikizira nkhaniyi kwa mtolankhani wofalitsa nkhani, "ndikuyembekezera kuvomerezedwa chaka chino, mwamsanga kuti apindule odwala kunenepa kwambiri aku China."

Wegovy ndi dzina lachingerezi lachingerezi la mankhwala a GLP-1 Semaglutide opangidwa ndi Novo Nordisk pazowonetsa zowonda, zomwe zidavomerezedwa ngati mankhwala ochepetsa thupi mu June 2021 ku United States.Mtsogoleri wamkulu wa Tesla, Musk, adatchulapo m'mabuku ochezera a pa Intaneti kuti adagwiritsa ntchito mankhwalawa kuti achepetse thupi, ndipo nthawi ina ankafunidwa ngati "mankhwala ozizwitsa ochepetsa thupi".

Ku China, jekeseni wa Semaglutide ndi mankhwala a pakamwa amangovomerezedwa kuti aziwonetsa matenda a shuga, omwe jekeseni ya simethicone idzavomerezedwa kuti igulitse ku China mu April 2021, ndipo pambuyo pake lowetsani mndandanda wa inshuwalansi ya umoyo wa dziko mu 2022;Oral Semaglutide idavomerezedwa mu Januwale chaka chino, ndipo idakhala mankhwala oyamba a pakamwa a GLP-1 ovomerezeka kuti agulitse ku China.

Monga woimira mankhwala a GLP-1, Semaglutide yakhala yopambana pamalonda.Lipoti lazachuma la Novo Nordisk la 2023 likuwonetsa kuti malonda a Wegovy adakwera 406% mpaka $ 4.6 biliyoni, kutsogola mayendedwe apadziko lonse a GLP-1.Komanso chifukwa cha izi, makampani ambiri ogulitsa mankhwala apakhomo amakonza Semaglutide biosimilar chitukuko cha mankhwala, koma ambiri ali m'chipatala choyambirira, monga Liju Group (000513), Han Yu Pharmaceutical (300199) ndi makampani ena ambiri osokoneza bongo adalengeza kale kuti Semaglutide ya kampaniyo. jakisoni adavomerezedwa kuti achite mayesero azachipatala pazowonetsa zokhudzana ndi kulemera.

Ndikoyenera kunena kuti, pamodzi ndi Novo Nordisk amadziwika kuti "GLP-1 duo" LLY ikulimbikitsanso mndandanda wa mankhwala ochepetsa thupi a GLP-1 Tirzepatide ku China, omwe akuyembekezekanso kuvomerezedwa m'nyumba.2023 August, LLY China idalengeza izi, malinga ndi tsamba lovomerezeka la Drug Evaluation Center la State Drug Administration.Kulembetsa kwa jekeseni wa Tirzepatide kuti apititse patsogolo kasamalidwe ka kulemera kwanthawi yayitali kwa odwala onenepa kwambiri omwe ali ndi kunenepa kwambiri kapena omwe ali ndi vuto limodzi lokhudzana ndi kulemera chifukwa cha zakudya zopatsa mphamvu zochepa komanso zolimbitsa thupi zochulukirapo zavomerezedwa mwalamulo.

Chizindikiro cha matenda a shuga a Tirzepatide chidavomerezedwa ku US mu Meyi 2022, ndipo mankhwalawa adapereka ndalama zokwana $483 miliyoni kwa Lilly mu 2022. miyezi iwiri ya ndalama zosakwana $176 miliyoni.

Ndi mankhwala a Novo Nordisk ndi LLY GLP-1 omwe akuyembekezeka kuvomerezedwa kuti azitha kuwonda ku China, mpikisano pakati pa Novo Nordisk ndi LLY pa track ya GLP-1 ukhoza kuyamba posachedwa ku China.